JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Выпуски журналов
Medical Radiology and Radiation Safety. 2024. Vol. 69. № 6
DOI:10.33266/1024-6177-2024-69-6-77-81
D.A. Ginevsky, P.V. Izhevskij, T.N. Laschenova
Stochastic Model of the Processe of the Spread of Platinum Drugs in Tumor Tissues
A.I. Burnazyan Federal Medical Biophysical Center, Moscow, Russia
Contact person: D.A. Ginevsky, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Purpose: The study of the kinetics of the spatio-temporal distribution of cisplatin, as an agent capable of increasing the effectiveness of chemo-radiation therapy of solid tumors.
Material and methods: The material was the data of literature on the results of experiments of various groups of authors who studied the content of platinum in tissues on biopsy materials. The method of simulation mathematical modeling (in silico) is used, based on the biological patterns of tumor growth, morphofunctional changes in the structure of tumor cells and tissues. Model is based on reaction-diffusion equation system, coefficients of which are random functions of space and time. The model takes into account the sequence of processes from intravenous administration of cisplatin and its spatial distribution in various tissues, until the excretion of its addicts from the cell.
Results: The heterogeneity of the distribution of the concentration of platinum atoms in the tumor is shown. Perhaps this is due to the varying degree of vascularization of tissues, the rate of metabolism of the tumor occurring in the outer layer and in its hypoxic core. These processes lead to significant errors when evaluating the biopsy data obtained in the experiments and the analysis of platinum content in the biopsy.
Conclusions: The calculation assessments of the distribution of platinum atoms in the tumor are consistent with the literature on the concentration of cisplatin in biopsy samples for carcinoma. The results of the calculations on the described model are fair, taking into account the morphological type, the size of the tumor and the plan of the administration of the drug. For other conditions (cancer types, treatment regimens, etc.), new calculations are necessary. To increase the efficiency of combined chemo-radiation therapy, cisplatin should be introduced at least 72 hours before the start of radiation therapy.
Keywords: cemo-radiation therapy, cislatin, tumors, mathematical modeling
For citation: Ginevsky DA, Izhevskij PV, Laschenova TN. Stochastic Model of the Processe of the Spread of Platinum Drugs in Tumor Tissues. Medical Radiology and Radiation Safety. 2024;69(6):77–81. (In Russian). DOI:10.33266/1024-6177-2024-69-6-77-81
References
1. Zlokachestvennyye Novoobrazovaniya v Rossii v 2022 Godu (Zabolevayemost’ i Smertnost’)=Malignant Neoplasms in Russia in 2022 (Incidence and Mortality). Ed. A.D.Kaprin. Moscow, National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation Publ., 2023. 275 p. (In Russ.).
2. Bucci МК, Bevan A, Roach М. Advances in Radiation Therapy: Conventional to 3D, to IMRT, to 4D and Beyond. СA Cancer Clin. 2005;55;2:117–34.
3. Sukhikh Е.S., Sukhikh L.G., Anikeyeva O.YU., Izhevs-
kiy P.V., Sheyno I.N. Dosimetric Evaluation for Various Methods of Combined Radiotherapy of Cervical Cancer. Meditsinskaya Radiologiya i Radiatsionnaya Bezopasnost’= Medical Radiology and Radiation Safety. 2019;64;1:45-52
(In Russ.). doi: 10.12737/article_5c55fb4a074ee1.27347494
4. Dar’yalova S.L., et al. The Use of Antitumor Drugs as Modifiers of the Reaction of Malignant Tumors to Radiation Therapy. Sovremennyye Tendentsii Razvitiya Lekarstvennoy Terapii Opukholey = Modern Trends in the Development of Drug Therapy for Tumors. Moscow Publ., 1998. 76 p.
(In Russ.).
5. Bolotina L.V., Vladimirova L.YU., Den’gina N.V., Novik A.V., Romanov I.S. Practical Recommendations for the Treatment of Malignant Tumors of the Head and Neck. Malignant Tumors. 2016;452;55-63. (In Russ.). doi: 10.18027/2224-5057-2016-452-55-63
6. URL https://www.rlsnet.ru/drugs/cisplatin-ronc-58005 (accessed date: 25.05.2024).
7. Grokhovskiy S. L., Zubarev V. Ye. Specific Cleavage of 2-Helix Dna Induced by Ionization of Platinum Atom by X-Ray Irradiation. Reports of the Academy of Sciences of the USSR Publ., 1990;313;6:1500-4 (In Russ.).
8. Ginevskiy A.F., Ginevskiy D.A., Izhevskiy P.V. Numerical Modeling of Space-time Distribution of a Drug Agent in Biological Tissue. Mathematical Modeling. 2021;33;11:3-17. https://doi.org/10.20948/mm-2021-11-01
9. Biston М.С., Jouber A., Adam J.F., Elleaume H., Bohic H., Charvet A.M., Estève F., Foray N., Balosso J. Cure of Fisher Rats Bearing Radioresistant F98 Glioma Treated with cis-Platinum and Irradiated with Monochromatic Synchrotron X-Rays. Cancer Research. 2004;Apr 1;64:2317-23.
10. Zamboni W.C., Gervais A.C., Egorin M.J., Schellens J.H., Hamburger D.R., Delauter B.J., Grim A., Zuhowski E.G., Joseph E., Pluim D., Potter D.M., Eiseman J.L. Inter- and Intratumoral Disposition of Platinum in Solid Tumors after Administration of Cisplatin. Clin Cancer Res. 2002;Sep;8;9:2992-9. PMID: 12231546.
11. Tsyushi Ch. Konformatsionnyye Izmeneniya Molekuly Dnk pri Vzaimodeystvii s Koordinatsionnymi Soyedineniyami Platiny i Serebra = Conformational Changes in the DNA Molecule During Interaction with Coordination Compounds of Platinum and Silver. .Candidate’s Thesis (Physical and Mathematical Sciences). St. Petersburg Publ., 2015. 120 p. (In Russ.).
12. Akaboshi M., Kawai K., Maki H., Akuta K., Ujeno У., Miyahara T. The Number of Platinum Atoms Binding to DNA, RNA and Protein Molecules of HeLa Cells Treated with Cisplatin at Its Mean Lethal Concentration. Jpn. J. Cancer Res. 1992;Мау;83:522-6.
13. Holding JD, Lindup WE, Bowdler DA, Siodlak MZ, Stell PM. Disposition and Tumour Concentrations of Platinum in Hypoalbuminaemic Patients after Treatment with Cisplatin for Cancer of the Head and Neck. Br. J. Clin. Pharmac. 1991;32:173-9.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.07.2024. Accepted for publication: 25.09.2024.
Medical Radiology and Radiation Safety. 2024. Vol. 69. № 6
DOI:10.33266/1024-6177-2024-69-6-82-86
M.A. Iliin1, M.V. Podolskaya2
Rotational Volume-Modulated Radiation Therapy of Unresectable
Localised Form of Castleman’s Disease
¹ FSBI Russian Scientific Center for Roentgenoradiology, Moscow, Russia
2 RUDN University, Moscow, Russia
Contact person: Mariya V. Podolskaya, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Rеlevance: Castleman’s disease is a relatively rare heterogeneous group of lymphoproliferative diseases, the incidence of the localized form is 15, and the multicentric form is about 5 people per 1 million population. Currently, surgical treatment is the most radical in the treatment of localized forms of Castleman’s disease, and in cases where the clinical situation is considered unresectable, the treatment strategy is not strictly defined. Studies of the effect of radiation therapy on the survival rates of patients with Castleman’s disease remain isolated to this day, up to the description of individual clinical cases. This is due to the low incidence of this pathology, which does not allow for high-power randomized clinical trials. However, empirical accumulation of experience suggests that conducting remote radiation therapy in total doses of 40 Gy helps to achieve long-term local control. The use of modern methods of radiation therapy in the form of volume-modulated radiation therapy makes it possible to avoid serious post-radiation damage to healthy organs and tissues adjacent to the tumor, and can help in achieving stable local control in the treatment of unrecoverable forms. It is possible to use DLT protocols used in the treatment of lymphomas, which may be comparable in their effectiveness for Castleman’s disease, which requires subsequent research.
Purpose: Аn analysis of a rare clinical observation of the successful use of rotational volume-modulated radiation therapy in the treatment of an unresectable localized form of Castleman’s disease.
Material and methods: The search and analysis of literature data in Russian and English for the period from 2000 to 2023 in the databases Medline/PubMed, RSCI/Elibrary, CyberLeninka, Google Scholar, devoted to the diagnosis and treatment of Castleman’s disease. Clinical observation of the use of rotational volume-modulated radiation therapy in the treatment of an unresectable localized form of Castleman’s disease with lesions of the supraclavicular lymph nodes (hyaline-vascular type, unicentric variant).
Results: Rotational volume-modulated radiation therapy of an unresectable localized form of Castleman’s disease can have a stable and safe consolidating effect in the form of long-term local control.
Keywords: Castleman’s disease, radiation therapy, clinical case
For citation: Iliin MA, Podolskaya MV. Rotational Volume-Modulated Radiation Therapy of Unresectable Localised Form of Castleman’s Disease. Medical Radiology and Radiation Safety. 2024;69(6):82–86. (In Russian). DOI:10.33266/1024-6177-2024-69-6-82-86
References
1. Dispenzieri A., Armitage J.O, Loe M.J, et al. The Clinical Spectrum of Castleman’s Disease. Am. J. Hematol. 2012; Nov;87;11:997–1002. DOI: 10.1002/ajh.23291.
2. Simpson D. Epidemiology of Castleman Disease. Hematol. Oncol. Clin. N. Am. 2018;32:1–10. DOI: 10.1016/j.hoc.2017.09.001.
3. Talat N., Schulte K.M. Castleman’s Disease: Systematic Analysis of 416 Patients from the Literature. Oncologist. 2011;16:1316-1324. DOI: 10.1634/theoncologist.2011-0075.
4. Iwaki N., Fajgenbaum D.C., Nabel C.S, et al. Clinicopathologic Analysis of TAFRO Syndrome Demonstrates a Distinct Subtype of HHV-8-Negative Multicentric Castleman Disease. Am. J. Hematol. 2016;91:220-226. DOI: 10.1002/ajh.24242.
5. Nishimura Y., Hanayama Y., Fujii N., et al. Comparison of the Clinical Characteristics of TAFRO Syndrome and Idiopathic Multicentric Castleman Disease in General Internal Medicine: a 6-year Retrospective Study. Intern. Med. J. 2020;50:184-191. DOI:10.1111/imj.14404.
6. Talat N., Belgaumkar A.P., Schulte K.M. Surgery in Castleman’s Disease: a Systematic Review of 404 Published Cases. Ann. Surg. 2012;255:677-684. DOI: 10.1097/SLA.0b013e318249dcdc.
7. Wu D., Lim M.S., Jaffe E.S. Pathology of Castleman Disease. Hematol. Oncol. Clin. North. Am. 2018;32:37-52. DOI: 10.1016/j.hoc.2017.09.004.
8. Fajgenbaum D.C., Uldrick T.S., Bagg A., et al. International, Evidence-Based Consensus Diagnostic Criteria for HHV-8-Negative/Idiopathic Multicentric Castleman Disease. Blood. 2017;129:1646-1657. DOI: 10.1016/j.hoc.2017.09.004.
9. Van Rhee F., Oksenhendler E., Srkalovic G., et al. International Evidence-Based Consensus Diagnostic and Treatment Guidelines for Unicentric Castleman Disease. Blood. Adv. 2020;4:6039-6050. DOI: 10.1182/bloodadvances.2020003334.
10. Van Rhee F., Voorhees P., Dispenzieri A., et al. International, Evidence-Based Consensus Treatment Guidelines for Idiopathic Multicentric Castleman Disease. Blood. 2018;132:2115-2124. doi:10.1182/blood-2018-07-862334.
11. Van Rhee F., Casper C., Voorhees P.M., et al. Long-Term Safety of Siltuximab in Patients with Idiopathic Multicentric Castleman Disease: a Prespecified, Open-Label, Extension Analysis of Two Trials. Lancet. Haematol. 2020;7:e209-e217. DOI:10.1016/s2352-3026(19)30257-1.
12. Van Rhee F., Rosenthal A., Kanhai K., et al. Siltuximab is Associated with Improved Progression-Free Survival in Idiopathic Multicentric Castleman Disease. Blood. Adv. 2022;6:4773-4781. DOI: 10.1182/bloodadvances.2022007112.
13. Chronowski G.M., Ha C.S., Wilder R.B., et al. Treatment of Unicentric and Multicentric Castleman Disease and the Role of Radiotherapy. Cancer. 2001;92:670-676. DOI:10.1002/1097-0142(20010801)92:3<670:aid-cncr1369>3.0.co;2-q
14. Matthiesen C., Ramgopol R., Seavey J., Ahmad S., Herman T. Intensity Modulated Radiation Therapy (IMRT) for the Treatment of Unicentric Castlemans Disease: a Case Report and Review of the Use of Radiotherapy in the Literature. Radiology and Oncology. 2012;46;3:265-70. DOI:10.2478/v10019-012-0008-0
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.07.2024. Accepted for publication: 25.09.2024.
Medical Radiology and Radiation Safety. 2024. Vol. 69. № 6
А.В. Титов, Е.И. Клименко, С.М. Шинкарев, В.Н. Яценко
Памяти профессора Константина Ивановича Гордеева
(к 100-летию со дня рождения 10.12.1924–31.03.2005)
Константи Иванович Гордеев
10.12.1924–31.03.2005
10 декабря 2024 г. исполняется 100 лет со дня рождения видного советского и российского ученого – профессора, доктора технических наук, заслуженного деятеля науки РСФСР, лауреата Ленинской и Государственной премии СССР, прекрасного человека Константина Ивановича Гордеева. Его имя неразрывно связано с историей Семипалатинского полигона и Института биофизики МЗ СССР.
Константин Иванович родился 10.12.1924 в г. Таганроге Ростовской области. Во время Великой Отечественной войны в семнадцать лет, как большинство его сверстников, добровольцем ушел на фронт. В боях был трижды ранен. За проявленные мужество и героизм награжден орденом Красной звезды, двумя медалями «За отвагу», медалью «За боевые заслуги» и другими боевыми наградами, а в 1985 г. – орденом Отечественной войны I степени.
К.И. Гордеев – участник ВОВ
После окончания войны в 1951–1956 гг. учился в Военной академии химической защиты им. К.Е. Ворошилова. По окончании академии в 1957 г. был направлен на Семипалатинский полигон, где прошел путь от младшего научного сотрудника до руководителя службы радиационной безопасности полигона. На полигоне он занимался не только становлением службы радиационной безопасности, но и научной работой, подготовив кандидатскую диссертацию. Диссертацию успешно защитил в Институте биофизики МЗ СССР. Учёный совет признал, что она по научной значимости соответствует докторской, и установил срок представления доработанного варианта к защите докторской диссертации, с чем Константин Иванович блестяще справился.
После увольнения из Вооруженных Сил в 1970 г. Константин Иванович назначается заведующим проблемной научной лабораторией Института биофизики МЗ СССР, а в дальнейшем – заместителем директора по научной работе
(с 1980 г.) и главным научным сотрудником института (1989–2004 гг.).
Основные направления научных исследований – проблемы обеспечения радиационной безопасности персонала и населения в районе ядерных объектов и при специальном и мирном использовании ядерной энергии.
Глубокая эрудиция в специальных вопросах, незаурядные организаторские способности позволили ему успешно осуществлять научное руководство крупными комплексными исследованиями в натурных условиях. Под непосредственным руководством К.И. Гордеева проводились многофакторные научные исследования, имеющие важное государственное и оборонное значение. Его самобытный научный стиль объединял талант ученого-экспериментатора и организатора комплексных исследований. За цикл работ в данном направлении Константин Иванович вместе с коллегами стал лауреатом Государственной премии СССР (1977 г.) и Ленинской премии (1985 г.).
Константин Иванович с сотрудниками лаборатории (конец 70-годов)
Весомый вклад Константин Иванович внес в ликвидацию последствий аварии на Чернобыльской АЭС, в разработку нормативных и методических документов по регламентации предельно допустимых уровней радиоактивного загрязнения, а также доз облучения персонала и населения. На основании разработанных под его руководством документов принимались ответственные правительственные решения по вопросам радиационной защиты, эвакуации населения и его последующего возвращения в ранее загрязненные районы. За участие в ликвидации последствий аварии на ЧАЭС он награжден орденом Ленина (1986 г.).
В конце 1990-х – начале 2000-х гг. Константин Иванович совместно с американскими учеными работал над созданием универсальной методологии реконструкции доз внешнего и внутреннего облучения населения, проживающего на следах радиоактивных выпадений, обусловленных проведением ядерных испытаний на Семипалатинском и Невадском испытательных полигонах. Данная методология была успешно применена для оценки доз в ряде эпидемиологических кейс-контрольных и когортных исследований и внесла значимый вклад в реалистичную оценку радиационного риска для населения, подвергшегося радиационному воздействию.
К.И. Гордеев (4-й слева) – менеджер российско-американского проекта в группе российских и американских специалистов
Константин Иванович являлся председателем специализированного Совета Института биофизики по защите докторских и кандидатских диссертаций, членом Научной комиссии по радиационной защите и нескольких научно-координационных Советов по специальным вопросам науки и техники.
Автор и соавтор более 300 научных трудов. Подготовил 4 докторов и 14 кандидатов наук. За плодотворную деятельность по развитию науки Константин Иванович в 1997 г. был награжден орденом Дружбы.
В Константине Ивановиче гармонично сочетались интеллигентность, доброжелательность, отзывчивость, общительность, добросовестность, трудолюбие, преданность делу и товарищам по работе, душевная теплота и щедрость. Одновременно он предъявлял к себе и сотрудникам высокие требования к качеству и срокам выполнения работ.
К.И. Гордеев заслуженно пользовался высоким авторитетом и уважением коллег Института биофизики МЗ СССР и сотрудников других организаций, которым посчастливилось работать с ним.
PDF (RUS) Full-text article (in Russian)
Medical Radiology and Radiation Safety. 2024. Vol. 69. № 6
DOI:10.33266/1024-6177-2024-69-6-87-93
G.G. Shimchuk, A.V. Skobliakov, A.A. Golubev, A.V. Kantsyrev, Gr.G. Shimchuk
Assessment of the Possibility of Verification of Proton Dose Distributions by the Method of Induced Positron Activity in Human Tissue
National Research Center “Kurchatov Institute”
Contact person: G.G. Shimchuk, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
A computational assessment was made of the possibility of verifying dose distributions during proton radiation therapy using PET imaging of positron activity in human tissues, which was formed as a result of proton irradiation. To compare the dose distribution of a particle energy-modulated proton beam with a diameter of 10 mm with an initial particle energy of 100 MeV, ensuring uniform irradiation of the target in a 13 mm zone (at the level of 90 % of the radiation dose) at the end of the particle path, with a map of induced activity from the radionuclides 11C, 13N and 15O, numerical calculations were performed in a Monte–Carlo code using the Geant4 simulation program. In the modeling process, a volume with dimensions of 50 × 50 × 100 mm was used, simulating soft tissues of the human body with a density of 1 g/cm3, consisting of hydrogen atoms (62 %), carbon (12 %), oxygen (24 %) and nitrogen (1.1 %). The cross sections for the formation of radionuclides 11C, 13N and 15O in the reactions 12C(p, pn)11C, 14N(p, α)11C, 16O(p, αpn)11C, 14N(p, pn)13N, 16O(p, α)13N, 16O(p, pn)15O have been calculated, which were used to calculate the distributions of positron activity in the irradiated volume. Taking into account the short half-lives of the radionuclides under consideration (primarily oxygen-15), calculations of isoactivities and depth distributions of accumulated radioactivities were performed for various time intervals after irradiation.
The performed computational modeling of the distributions of activities of radionuclides 11C, 13N and 15O during the passage of a modulated proton beam, taking into account the decay of produced radionuclides after irradiation, shows that by recording for 15 minutes the induced activity of PET radionuclides 2 minutes after irradiation, it is possible to obtain data on the compliance of the planned and irradiation of tumors performed during proton therapy. However, small levels of generated activity (at a level of 2 Gy for finely fractionated irradiations) require a device with high efficiency in recording annihilation radiation and high spatial resolution at the level of 1.5–2.0 mm.
Key words: proton irradiation, radionuclides, induced activity, PET, dose fields, verification
For citation: Shimchuk GG, Skobliakov AV, Golubev AA, Kantsyrev AV, Shimchuk GrG. Assessment of the Possibility of Verification of Proton Dose Distributions by the Method of Induced Positron Activity in Human Tissue. Medical Radiology and Radiation Safety. 2024;69(6):87–93. (In Russian). DOI:10.33266/1024-6177-2024-69-6-87-93
References
1. Goitein M. Radiation Oncology –A Physicist’s Eye View. New York, Springer, 2008.
2. Koehler AM, Schneider RJ, Sisterson JM. Flattening of Proton Dose Distributions for Large-Field Radiotherapy. Med. Phys. 1977;4:297–301.
3. Grusell E, et al. A general Solution to Charged Particle Beam Flattening Using an Optimized Dual-Scattering-Foil Technique, with Application to Proton Therapy Beams. Phys. Med. Biol. 1994;39:2201–16.
4. Kanai T, et al. Spot Scanning System for Proton Radiotherapy. Med. Phys. 1980;7:365–9.
5. Pedroni E, et al. The 200-MeV Proton Therapy Project at the Paul Scherrer Institute: Conceptual Design and Practical Realization. Med. Phys. 1995;22:37–53
6. Kraft G. Tumortherapy with Ion Beams. Nucl. Instrum. and Methods Phys. Res. A. 2000;454:1–10.
7. Zenklusen S, Pedroni E, Meer D. A Study on Repainting Strategies for Treating Moderately Moving Targets with Proton Pencil Beam Scanning for the New Gantry 2 at PSI. Phys. Med. Biol. 2010;55:5103–21.
8. Geant 4: User’s Guide for Application Developers. URL: https://geant4-userdoc.web.cern.ch/UsersGuides/ForApplicationDeveloper/fo/BookForApplicationDevelopers.pdf
9. Wen Luo, Hao-yang Lan, Yi Xu, Dimiter L. Balabanski. Implementation of the n-Body Monte-Carlo Event Generator into the Geant4 toolkit for Photonuclear Studies. Nuclear Instruments and Methods in Physics Research A. 2017;849:49-54. doi: 10.1016/j.nima.2017.01.010
10. Jae Won Shin. A Data-Based Photonuclear Reaction Model for GEANT4. Nuclear Instruments and Methods in Physics Research B. 2015;358:194-200.
11. TALYS. URL: https://www-nds.iaea.org/talys/
12. Geant 4: Physics List Guide. URL: https://geant4- userdoc.web.cern.ch/UsersGuides/PhysicsListGuide/fo/ PhysicsListGuide.pdf
13. Geant 4: User’s Guide for Toolkit Developers. URL: https://geant4userdoc.web.cern.ch/UsersGuides/ForToolkitDeveloper/fo/BookForToolkitDeveloper.pdf
14. Geant 4 Physics: Physics Reference Manual. URL: https://geant4- userdoc.web.cern.ch/UsersGuides/PhysicsReferenceManual/fo/ PhysicsReferenceManual.pdf
15. LibInterpolate. URL: https://github.com/CD3/libInterpolate.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The work was carried out as part of the fulfillment of the state task of the Kurchatov Institute Research Center.
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.07.2024. Accepted for publication: 25.09.2024.
CONTENTS № 6 - 2024
View or download the full issue in PDF (Russian)
|
RADIATION BIOLOGY |
5 |
Deshevoi Yu.B., Lebedev V.G., Nasonova T.A., Dobrynina O.A., |
|||
|
12 |
The Response of Mouse Microglia Cells SIM-A9 to γ-Radiation Shaposhnikova D.A., Moskaleva E.Yu., Vysotskaya O.V., Komova O.V., Koshlan IV, Kondratiev K.V. |
||||
| RADIATION SAFETY |
19 |
Kosenkov A.A., Lyaginskaya A.M. |
|||
|
27 |
Andrianova I.E., Rozhdestvensky L.M., Efimova I.L. |
||||
| RADIATION MEDICINE |
33 |
Aksenenko A.V., Samoilov A.S., Parinov O.V., Bushmanov A.Yu., |
|||
|
38 |
Sycheva L.P., Bobrov A.F., Kiselev S.M., Novikova T.M. |
||||
|
42 |
Galstian I.A., Bushmanov A.Yu., Shcherbatykh O.V,. Nugis V.Yu., |
||||
| RADIATION EPIDEMIOLOGY |
51 |
Zavyalov D.A., Krestinina L.Yu. |
|||
|
RADIATION DIAGNOSTICS |
56 |
Ussov W.Yu., Belyanin M.L., Borodin O.Y., Bezlepkin A.I., Churin A.A., Shimanovsky N.L. |
|||
|
64 |
Methods for Evaluating the Energy Processes of the Brain (Literature Review) Zvereva Z.F., Vanchakova N.P., Miroshnik E.V., Torubarov F.S. |
||||
| RADIATION
THERAPY |
71 |
Combined Method for Treating Orophynary Cancer Udalov Yu.D., Vorobiev A.A., Nezvetsky A.V., Kiselev V.A. |
|||
|
77 |
Stochastic Model of the Processe of the Spread of Platinum Drugs in Tumor Tissues Ginevsky D.A., Izhevskij P.V., Laschenova T.N. |
||||
|
82 |
Rotational Volume-Modulated Radiation Therapy of Unresectable Localised Form of Castleman’s Disease Iliin M.A., Podolskaya M.V. |
||||
| RADIATION PHYSICS, TECHNIQUE AND DOSIMETRY |
87 |
Shimchuk G.G., Skobliakov A.V., Golubev A.A., Kantsyrev A.V., |
|||
|
ANNIVERSARY |
94 |
Titov A.V., Klimenko E.I., Shinkarev S.M., Yatsenko V.N. |
|||
| BIBLIOGRAPHY |
97 |
Materials Published in the Journal ‟Medical Radiology and Radiation Safety” in 2024, Vol. 69 |
|||